Linzess 0.29 MG Oral Capsule

Details

Generic Name: LINACLOTIDE

Brand Name: Linzess

Substance Name(s):
LINACLOTIDE

OVERDOSAGE

10 Single LINZESS doses of 2897 mcg were administered to 22 healthy subjects; the safety profile in these subjects was consistent with that in the overall LINZESS-treated population, with diarrhea being the most commonly reported adverse reaction.

DESCRIPTION

11 LINZESS (linaclotide) is a guanylate cyclase-C (G-CC) agonist.

Linaclotide is a 14-amino acid peptide with the following chemical name: L-cysteinyl-L-cysteinyl-L-glutamyl-L-tyrosyl-L-cysteinyl-L-cysteinyl-L-asparaginyl-L-prolyl-L-alanyl-L-cysteinyl-L-threonyl-glycyl-L-cysteinyl-L-tyrosine, cyclic (1-6), (2-10), (5-13)-tris (disulfide).

The molecular formula of linaclotide is C 59 H 79 N 15 O 21 S 6 and its molecular weight is 1526.8.

The amino acid sequence for linaclotide is shown below: Linaclotide is an amorphous, white to off-white powder.

It is slightly soluble in water and aqueous sodium chloride (0.9%).

LINZESS contains linaclotide-coated beads in hard gelatin capsules.

LINZESS is available as 72 mcg, 145 mcg and 290 mcg capsules for oral administration.

The inactive ingredients of LINZESS 72 mcg capsules include: calcium chloride dihydrate, L-histidine, microcrystalline cellulose, polyvinyl alcohol, and talc.

The components of the capsule shell include gelatin and titanium dioxide.

The inactive ingredients of LINZESS 145 mcg and 290 mcg capsules include: calcium chloride dihydrate, hypromellose, L-leucine, and microcrystalline cellulose.

The components of the capsule shell include gelatin and titanium dioxide.

LINZESS (linaclotide) is a guanylate cyclase-C (G-CC) agonist.

CLINICAL STUDIES

14 14.1 Irritable Bowel Syndrome with Constipation (IBS-C) The efficacy of LINZESS for the management of symptoms of IBS-C was established in two double-blind, placebo-controlled, randomized, multicenter trials in adult patients (Trials 1 (NCT00948818) and 2 (NCT00938717)).

A total of 800 patients in Trial 1 and 804 patients in Trial 2 [overall mean age of 44 years (range 18 to 87 years), 90% female, 77% white, 19% black, and 12% Hispanic] received treatment with LINZESS 290 mcg or placebo once daily and were evaluated for efficacy.

All patients met Rome II criteria for IBS and were required, during the 2-week baseline period, to meet the following criteria: a mean abdominal pain score of at least 3 on a 0-to-10-point numeric rating scale less than 3 complete spontaneous bowel movements (CSBMs) per week [a CSBM is a spontaneous bowel movement (SBM) that is associated with a sense of complete evacuation; a SBM is a bowel movement occurring in the absence of laxative use], and less than or equal to 5 SBMs per week.

The trial designs were identical through the first 12 weeks, and thereafter differed only in that Trial 1 included a 4-week randomized withdrawal (RW) period, and Trial 2 continued for 14 additional weeks (total of 26 weeks) of double-blind treatment.

During the trials, patients were allowed to continue stable doses of bulk laxatives or stool softeners but were not allowed to take laxatives, bismuth, prokinetic agents, or other drugs to treat IBS-C or chronic constipation.

Efficacy of LINZESS was assessed using overall responder analyses and change-from-baseline endpoints.

Results for endpoints were based on information provided daily by patients in diaries.

The 4 primary efficacy responder endpoints were based on a patient being a weekly responder for either at least 9 out of the first 12 weeks of treatment or at least 6 out of the first 12 weeks of treatment.

For the 9 out of 12 weeks combined primary responder endpoint, a patient had to have at least a 30% reduction from baseline in mean abdominal pain, at least 3 CSBMs and an increase of at least 1 CSBM from baseline, all in the same week, for at least 9 out of the first 12 weeks of treatment.

Each of the 2 components of the 9 out of 12 weeks combined responder endpoint, abdominal pain and CSBMs, was also a primary endpoint.

For the 6 out of 12 weeks combined primary responder endpoint, a patient had to have at least a 30% reduction from baseline in mean abdominal pain and an increase of at least 1 CSBM from baseline, all in the same week, for at least 6 out of the first 12 weeks of treatment.

To be considered a responder for this analysis, patients did not have to have at least 3 CSBMs per week.

The efficacy results for the 9 out of 12 weeks and the 6 out of 12 weeks responder endpoints are shown in Tables 3 and 4, respectively.

In both trials, the proportion of patients who were responders to LINZESS 290 mcg was statistically significantly higher than with placebo.

Table 3: Efficacy Responder Rates in the Two Placebo-controlled IBS-C Trials: At Least 9 Out of 12 Weeks Trial 1 Trial 2 LINZESS 290 mcg (N=405) Placebo (N=395) Treatment Difference [95% CI] LINZESS 290 mcg (N=401) Placebo (N=403) Treatment Difference [95% CI] Combined Responder* (Abdominal Pain and CSBM Responder) 12% 5% 7% [3.2%, 10.9%] 13% 3% 10% [6.1%, 13.4%] Abdominal Pain Responder* (≥ 30% Abdominal Pain Reduction) 34% 27% 7% [0.9%, 13.6%] 39% 20% 19% [13.2%, 25.4%] CSBM Responder* (≥ 3 CSBMs and Increase ≥1 CSBM from Baseline) 20% 6% 13% [8.6%, 17.7%] 18% 5% 13% [8.7%, 17.3%] * Primary Endpoints Note: Analyses based on first 12 weeks of treatment for both Trials 1 and 2 CI =Confidence Interval Table 4: Efficacy Responder Rates in the Two Placebo-controlled IBS-C Trials: At Least 6 Out of 12 Weeks Trial 1 Trial 2 LINZESS 290 mcg (N=405) Placebo (N=395) Treatment Difference [95% CI] LINZESS 290 mcg (N=401) Placebo (N=403) Treatment Difference [95% CI] Combined Responder* (Abdominal Pain and CSBM Responder) 34% 21% 13% [6.5%, 18.7%] 34% 14% 20% [14.0%, 25.5%] Abdominal Pain Responder** (≥ 30% Abdominal Pain Reduction) 50% 37% 13% [5.8%, 19.5%] 49% 34% 14% [7.6%, 21.1%] CSBM Responder** (Increase ≥ 1 CSBM from Baseline) 49% 30% 19% [12.4%, 25.7%] 48% 23% 25% [18.7%, 31.4%] * Primary Endpoint, ** Secondary Endpoints Note: Analyses based on first 12 weeks of treatment for both Trials 1 and 2 CI =Confidence Interval In each trial, improvement from baseline in abdominal pain and CSBM frequency was seen over the first 12-weeks of the treatment periods.

For change from baseline in the 11-point abdominal pain scale, LINZESS 290 mcg began to separate from placebo in the first week.

Maximum effects were seen at weeks 6 – 9 and were maintained until the end of the study.

The mean treatment difference from placebo at week 12 was a decrease in pain score of approximately 1.0 point in both trials (using an 11-point scale).

Maximum effect on CSBM frequency occurred within the first week, and for change from baseline in CSBM frequency at week 12, the difference between placebo and LINZESS was approximately 1.5 CSBMs per week in both trials.

In each trial, in addition to improvements in abdominal pain and CSBM frequency over the first 12 weeks of the treatment period, improvements were observed in the following when LINZESS was compared to placebo: SBM frequency [SBMs/week], stool consistency [as measured by the Bristol Stool Form Scale (BSFS)], and amount of straining with bowel movements [amount of time pushing or physical effort to pass stool].

During the 4-week randomized withdrawal period in Trial 1, patients who received LINZESS during the 12-week treatment period were re-randomized to receive placebo or continue treatment on LINZESS 290 mcg.

In LINZESS-treated patients re-randomized to placebo, CSBM frequency and abdominal-pain severity returned toward baseline within 1 week and did not result in worsening compared to baseline.

Patients who continued on LINZESS maintained their response to therapy over the additional 4 weeks.

Patients on placebo who were allocated to LINZESS had an increase in CSBM frequency and a decrease in abdominal pain levels that were similar to the levels observed in patients taking LINZESS during the treatment period.

Trial 6 (NCT03573908) was a randomized, double-blind, placebo-controlled, parallel-group trial that evaluated the safety and efficacy of LINZESS in patients with IBS-C over a 12-week treatment period followed by a 4-week randomized withdrawal period.

A total of 614 patients [mean age of 47 years (range 18 to 85 years), 81% female, 63% white, 24% black, and 27% Hispanic] received treatment with LINZESS 290 mcg or placebo once daily and all patients met Rome III criteria for IBS-C.

The efficacy of LINZESS was assessed using a primary endpoint based on the mean abdominal score (composite of abdominal bloating, abdominal discomfort, and abdominal pain) across 12 weeks.

The secondary endpoint was a responder analysis based on at least a 2.5-point improvement in the abdominal score from baseline for at least 6 out of 12 weeks as shown in Table 5.

Table 5: Efficacy Endpoints in IBS-C Trial 6: Overall Change from Baseline in Abdominal Score and Responder Rates for a t Least 6 Out of 12 Weeks Trial 6 LINZESS 290 mcg (N= 306 ) Placebo (N= 308 ) Treatment Difference [95% CI] Baseline Abdominal Score 6.4 6.5 Least Squares 12-week Mean C hange from B aseline in Abdominal Score * -1.9 -1.2 -0.7 [-1.0, -0.4] Abdominal Score 6 of 12- W eek Responder* * 34% 18.5% 15.5% [8.6%, 22.3%] * Primary Endpoint, ** Secondary Endpoint Each abdominal symptom was rated on a 0-to-10-point numeric rating scale where 0=no [symptom] and 10=worst possible [symptom].

CI = Confidence Interval 14.2 Chronic Idiopathic Constipation (CIC) The efficacy of LINZESS for the management of symptoms of CIC was established in two double-blind, placebo-controlled, randomized, multicenter clinical trials in adult patients (Trials 3 and 4).

A total of 642 patients in Trial 3 and 630 patients in Trial 4 [overall mean age of 48 years (range 18 to 85 years), 89% female, 76% white, 22% black, 10% Hispanic] received treatment with LINZESS 145 mcg, 290 mcg, or placebo once daily and were evaluated for efficacy.

All patients met modified Rome II criteria for functional constipation.

Modified Rome II criteria were less than 3 Spontaneous Bowel Movements (SBMs) per week and 1 of the following symptoms for at least 12 weeks, which need not be consecutive, in the preceding 12 months: Straining during greater than 25% of bowel movements Lumpy or hard stools during greater than 25% of bowel movements Sensation of incomplete evacuation during greater than 25% of bowel movements Patients were also required to have less than 3 CSBMs per week and less than or equal to 6 SBMs per week during a 2-week baseline period.

Patients were excluded if they met criteria for IBS-C or had fecal impaction that required emergency room treatment.

The trial designs were identical through the first 12 weeks.

Trial 3 also included an additional 4-week randomized withdrawal (RW) period.

The efficacy of LINZESS was assessed using a responder analysis and change-from-baseline endpoints.

Results for endpoints were based on information provided daily by patients in diaries.

A CSBM responder in the CIC trials was defined as a patient who had at least 3 CSBMs and an increase of at least 1 CSBM from baseline in a given week for at least 9 weeks out of the 12-week treatment period.

The CSBM responder rates are shown in Table 6.

During the individual double-blind placebo-controlled trials, LINZESS 290 mcg did not consistently offer additional clinically meaningful treatment benefit over placebo than that observed with the LINZESS 145 mcg dose.

Therefore, the 145 mcg dose is the recommended dose.

Only the data for the approved 145 mcg dose of LINZESS are presented in Table 6.

In Trials 3 and 4, the proportion of patients who were CSBM responders was statistically significantly greater with the LINZESS 145 mcg dose than with placebo.

Table 6: Efficacy Responder Rates in the Two Placebo-controlled CIC Trials: at Least 9 Out of 12 Weeks Trial 3 Trial 4 LINZESS 145 mcg (N=217) Placebo (N=209) Treatment Difference [95% CI] LINZESS 145 mcg (N=213) Placebo (N=215) Treatment Difference [95% CI] CSBM Responder* (≥ 3 CSBMs and Increase ≥ 1 CSBM from Baseline) 20% 3% 17% [11.0%, 22.8%] 15% 6% 10% [4.2%, 15.7%] *Primary Endpoint CI=Confidence Interval CSBM frequency reached maximum level during week 1 and was also demonstrated over the remainder of the 12-week treatment period in Trial 3 and Trial 4.

For the mean change from baseline in CSBM frequency at week 12, the difference between placebo and LINZESS was approximately 1.5 CSBMs.

On average, patients who received LINZESS across the 2 trials had significantly greater improvements compared with patients receiving placebo in stool frequency (CSBMs/week and SBMs/week), and stool consistency (as measured by the BSFS).

In each trial, in addition to improvements in CSBM frequency over the first 12 weeks of the treatment period, improvements were observed in each of the following when LINZESS was compared to placebo: SBM frequency [SBMs/week], stool consistency [as measured by the BSFS], and amount of straining with bowel movements [amount of time pushing or physical effort to pass stool].

During the 4-week randomized withdrawal period in Trial 3, patients who received LINZESS during the 12-week treatment period were re-randomized to receive placebo or continue treatment on the same dose of LINZESS taken during the treatment period.

In LINZESS-treated patients re-randomized to placebo, CSBM and SBM frequency returned toward baseline within 1 week and did not result in worsening compared to baseline.

Patients who continued on LINZESS maintained their response to therapy over the additional 4 weeks.

Patients on placebo who were allocated to LINZESS had an increase in CSBM and SBM frequency similar to the levels observed in patients taking LINZESS during the treatment period.

A 72 mcg dose of LINZESS was established in a randomized, double-blind, placebo-controlled, multicenter clinical trial in adult patients (Trial 5).

A total of 1223 patients [overall mean age of 46 years (range 18 to 90 years), 77% female, 71% white, 24% black, 43% Hispanic] received treatment with LINZESS 72 mcg or placebo once daily and were evaluated for efficacy.

All patients met modified Rome III criteria for functional constipation.

Trial 5 was identical to Trials 3 and 4 through the first 12 weeks.

The efficacy of the 72 mcg dose was assessed using a responder analysis where a CSBM responder was defined as a patient who had at least 3 CSBMs and an increase of at least 1 CSBM from baseline in a given week for at least 9 weeks out of the 12-week treatment period, which was the same as the one defined in Trials 3 and 4.

The response rates for the CSBM responder endpoint were 13% for LINZESS 72 mcg and 5% for placebo.

The difference between LINZESS 72 mcg and placebo was 9% (95% CI: 4.8%, 12.5%).

A separate analysis was performed using an alternate CSBM responder definition.

In this analysis a CSBM responder was defined as a patient who had at least 3 CSBMs and an increase of at least 1 CSBM from baseline in a given week for at least 9 weeks out of the 12-week treatment period and at least 3 of the last 4 weeks of the treatment period.

The response rates for the alternate CSBM responder endpoint were 12% for LINZESS 72 mcg and 5% for placebo.

The difference between LINZESS 72 mcg and placebo was 8% (95% CI: 3.9%, 11.5%).

HOW SUPPLIED

16 /STORAGE AND HANDLING How Supplied LINZESS Capsule Strength Description Packaging NDC number 72 mcg White to off-white opaque hard gelatin capsules with gray imprint “FL 72” Bottle of 30 0456-1203-30 145 mcg White to off-white opaque hard gelatin capsules with gray imprint “FL 145” Bottle of 30 0456-1201-30 290 mcg White to off-white opaque hard gelatin capsules with gray imprint “FL 290” Bottle of 30 0456-1202-30 Storage Store at 25°C (77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].

Keep LINZESS in the original container.

Do not subdivide or repackage.

Protect from moisture.

Do not remove desiccant from the container.

Keep bottles tightly closed in a dry place.

GERIATRIC USE

8.5 Geriatric Use Irritable Bowel Syndrome with Constipation (IBS-C) Of 2219 IBS-C patients in the placebo-controlled clinical studies of LINZESS (Trials 1, 2, and 6), 154 (7%) were 65 years of age and over, while 34 (2%) were 75 years and over.

Clinical studies of LINZESS did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients.

Chronic Idiopathic Constipation (CIC) Of 2498 CIC patients in the placebo-controlled clinical studies of LINZESS (Trials 3, 4, and 5), 273 (11%) were 65 years of age and over, while 56 (2%) were 75 years and over.

Clinical studies of LINZESS did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.

In general, dose selection for an elderly patient should be cautious reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy.

DOSAGE FORMS AND STRENGTHS

3 LINZESS capsules are white to off-white opaque: 72 mcg; gray imprint “FL 72” 145 mcg; gray imprint “FL 145” 290 mcg; gray imprint “FL 290” Capsules: 72 mcg, 145 mcg and 290 mcg ( 3 )

MECHANISM OF ACTION

12.1 Mechanism of Action Linaclotide is structurally related to human guanylin and uroguanylin and functions as a guanylate cyclase-C (GC-C) agonist.

Both linaclotide and its active metabolite bind to GC-C and act locally on the luminal surface of the intestinal epithelium.

Activation of GC-C results in an increase in both intracellular and extracellular concentrations of cyclic guanosine monophosphate (cGMP).

Elevation in intracellular cGMP stimulates secretion of chloride and bicarbonate into the intestinal lumen, mainly through activation of the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, resulting in increased intestinal fluid and accelerated transit.

In animal models, linaclotide has been shown to both accelerate GI transit and reduce intestinal pain.

In an animal model of visceral pain, linaclotide reduced abdominal muscle contraction and decreased the activity of pain-sensing nerves by increasing extracellular cGMP.

INDICATIONS AND USAGE

1 LINZESS is indicated in adults for the treatment of: irritable bowel syndrome with constipation (IBS-C) chronic idiopathic constipation (CIC) LINZESS is a guanylate cyclase-C agonist indicated in adults for treatment of: Irritable bowel syndrome with constipation.

(IBS-C) ( 1 ) Chronic idiopathic constipation.

(CIC) ( 1 )

PEDIATRIC USE

8.4 Pediatric Use LINZESS is contraindicated in patients less than 6 years of age.

Avoid use of LINZESS in patients 6 years to less than 18 years of age [see Contraindications ( 4 ), Warnings and Precautions ( 5.1 )] .

The safety and effectiveness of LINZESS in patients less than 18 years of age have not been established.

In nonclinical studies, deaths occurred within 24 hours in neonatal mice (human age equivalent of approximately 0 to 28 days) following oral administration of linaclotide, as described below in Juvenile Animal Toxicity Data.

Because of increased intestinal expression of GC-C, patients less than 6 years of age may be more likely than patients 6 years of age and older to develop diarrhea and its potentially serious consequences.

LINZESS is contraindicated in patients less than 6 years of age.

Given the deaths in young juvenile mice and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of LINZESS in patients 6 years to less than 18 years of age.

Juvenile Animal Toxicity Data In toxicology studies in neonatal mice, oral administration of linaclotide at 10 mcg/kg/day caused deaths on post-natal day 7 (human age equivalent of approximately 0 to 28 days).

These deaths were due to rapid and severe dehydration produced by significant fluid shifts into the intestinal lumen resulting from GC-C agonism in neonatal mice [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )] .

Tolerability to linaclotide increases with age in juvenile mice.

In 2-week-old mice, linaclotide was well tolerated at a dose of 50 mcg/kg/day, but deaths occurred after a single oral dose of 100 mcg/kg.

In 3-week-old mice, linaclotide was well tolerated at 100 mcg/kg/day, but deaths occurred after a single oral dose of 600 mcg/kg.

PREGNANCY

8.1 Pregnancy Risk Summary Linaclotide and its active metabolite are negligibly absorbed systemically following oral administration [see Clinical Pharmacology ( 12.3 )] , and maternal use is not expected to result in fetal exposure to the drug.

The available data on LINZESS use in pregnant women are not sufficient to inform any drug-associated risk for major birth defects and miscarriage.

In animal developmental studies, no effects on embryo-fetal development were observed with oral administration of linaclotide in rats and rabbits during organogenesis at doses much higher than the maximum recommended human dosage.

Severe maternal toxicity associated with effects on fetal morphology were observed in mice ( see Data ) .

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.

In the United States general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data Animal Data The potential for linaclotide to cause harm to embryo-fetal development was studied in rats, rabbits and mice.

In pregnant mice, oral dose levels of at least 40,000 mcg/kg/day given during organogenesis produced severe maternal toxicity including death, reduction of gravid uterine and fetal weights, and effects on fetal morphology.

Oral doses of 5,000 mcg/kg/day did not produce maternal toxicity or any adverse effects on embryo-fetal development in mice.

Oral administration of up to 100,000 mcg/kg/day in rats and 40,000 mcg/kg/day in rabbits during organogenesis produced no maternal toxicity and no effects on embryo-fetal development.

Additionally, oral administration of up to 100,000 mcg/kg/day in rats during organogenesis through lactation produced no developmental abnormalities or effects on growth, learning and memory, or fertility in the offspring through maturation.

The maximum recommended human dose is approximately 5 mcg/kg/day, based on a 60-kg body weight.

Limited systemic exposure to linaclotide was achieved in animals during organogenesis (AUC = 40, 640, and 25 ng•hr/mL in rats, rabbits, and mice, respectively, at the highest dose levels).

Linaclotide and its active metabolite are not measurable in human plasma following administration of the recommended clinical dosages.

Therefore, animal and human doses should not be compared directly for evaluating relative exposure.

BOXED WARNING

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LINZESS is contraindicated in patients less than 6 years of age; in nonclinical studies in neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths due to dehydration [see Contraindications ( 4 ), Use in Specific Populations ( 8.4 )].

Avoid use of LINZESS in patients 6 years to less than 18 years of age [see Warnings and Precautions ( 5.1 ), Use in Specific Populations ( 8.4 )].

The safety and effectiveness of LINZESS have not been established in patients less than 18 years of age [see Use in Specific Populations ( 8.4 )].

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS See full prescribing information for complete boxed warning.

LINZESS is contraindicated in patients less than 6 years of age; in neonatal mice, linaclotide caused deaths due to dehydration.

( 4 , 8.4 ) Avoid use of LINZESS in patients 6 years to less than 18 years of age.

( 5.1 , 8.4 ) The safety and effectiveness of LINZESS have not been established in patients less than 18 years of age ( 8.4 ).

WARNING AND CAUTIONS

5 WARNINGS AND PRECAUTIONS Diarrhea: Patients may experience severe diarrhea.

If severe diarrhea occurs, suspend dosing and rehydrate the patient.

( 5.2 ) 5.1 Risk of Serious Dehydration in Pediatric Patients LINZESS is contraindicated in patients less than 6 years of age.

The safety and effectiveness of LINZESS in patients less than 18 years of age have not been established.

In neonatal mice (human age equivalent of approximately 0 to 28 days), linaclotide increased fluid secretion as a consequence of GC-C agonism resulting in mortality within the first 24 hours due to dehydration.

Due to increased intestinal expression of GC-C, patients less than 6 years of age may be more likely than patients 6 years of age and older to develop severe diarrhea and its potentially serious consequences.

Avoid use of LINZESS in pediatric patients 6 years to less than 18 years of age.

Although there were no deaths in older juvenile mice, given the deaths in young juvenile mice and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of LINZESS in pediatric patients 6 years to less than 18 years of age [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 ), Use in Specific Populations ( 8.4 )] .

2 Diarrhea Diarrhea was the most common adverse reaction of LINZESS-treated patients in the pooled IBS-C and CIC double-blind placebo-controlled trials.

The incidence of diarrhea was similar between the IBS-C and CIC populations.

Severe diarrhea was reported in 2% of 145 mcg and 290 mcg LINZESS-treated patients, and in <1% of 72 mcg LINZESS-treated CIC patients [see Adverse Reactions ( 6.1 )] .

In post-marketing experience, severe diarrhea associated with dizziness, syncope, hypotension and electrolyte abnormalities (hypokalemia and hyponatremia) requiring hospitalization or intravenous fluid administration have been reported in patients treated with LINZESS.

If severe diarrhea occurs, suspend dosing and rehydrate the patient.

INFORMATION FOR PATIENTS

17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Medication Guide ).

Advise patients: Diarrhea To stop LINZESS and contact their healthcare provider if they experience unusual or severe abdominal pain, and/or severe diarrhea, especially if in combination with hematochezia or melena [see Warnings and Precautions ( 5.2 )] .

Accidental Ingestion Accidental ingestion of LINZESS in children especially in children less than 6 years of age may result in severe diarrhea and dehydration.

Instruct patients to take steps to store LINZESS securely and out of reach of children, and to dispose of unused LINZESS [see Contraindications ( 4 ), Warnings and Precautions ( 5.1 , 5.2 )].

Administration and Handling Instructions To take LINZESS once daily on an empty stomach at least 30 minutes prior to the first meal of the day [see Dosage and Administration ( 2.2 )].

If a dose is missed, skip the missed dose and take the next dose at the regular time.

Do not take 2 doses at the same time.

To swallow LINZESS capsules whole.

Do not crush or chew capsules or capsule contents.

If adult patients have swallowing difficulties, LINZESS capsules can be opened and administered orally in either applesauce or with bottled water or administered with water via a nasogastric or gastrostomy tube, as described in the Medication Guide.

To keep LINZESS in the original container.

Do not subdivide or repackage.

Protect from moisture.

Do not remove desiccant from the container.

Keep bottles closed tightly in a dry place .

LINZESS ® is a registered trademark of Ironwood Pharmaceuticals, Inc.

Distributed by: Allergan USA, Inc.

Madison, NJ 07940 Marketed by: Allergan USA, Inc.

Ironwood Pharmaceuticals, Inc.

LINZESS® is a registered trademark of Ironwood Pharmaceuticals, Inc.

Allergan® and its design are trademarks of Allergan, Inc.

Patented.

See www.allergan.com/patents.

For more information, go to www.LINZESS.com or call 1-800-678-1605.

v3.0USPI1201

DOSAGE AND ADMINISTRATION

2 The recommended dosage in adults is: IBS-C: 290 mcg orally once daily.

( 2.1 ) CIC: 145 mcg orally once daily or 72 mcg orally once daily based on individual presentation or tolerability.

( 2.1 ) Administration Instructions ( 2.2 ): Take on empty stomach at least 30 minutes prior to first meal of the day.

Do not crush or chew LINZESS capsule or capsule contents.

For patients who have difficulty swallowing capsules whole or those with a nasogastric or gastrostomy tube, see full prescribing information for instructions for opening the capsule and administering with applesauce or water.

2.1 Recommended Dosage Irritable Bowel Syndrome with Constipation (IBS-C) The recommended dosage of LINZESS is 290 mcg orally once daily.

Chronic Idiopathic Constipation (CIC) The recommended dosage of LINZESS is 145 mcg orally once daily.

A dosage of 72 mcg once daily may be used based on individual presentation or tolerability.

2.2 Preparation and Administration Instructions Take LINZESS on an empty stomach, at least 30 minutes prior to the first meal of the day.

If a dose is missed, skip the missed dose and take the next dose at the regular time.

Do not take 2 doses at the same time.

Do not crush or chew LINZESS capsule or capsule contents.

Swallow LINZESS capsule whole.

For adult patients with swallowing difficulties, LINZESS capsules can be opened and administered orally in either applesauce or with water or administered with water via a nasogastric or gastrostomy tube.

Sprinkling of LINZESS beads on other soft foods or in other liquids has not been tested.

Oral Administration in Applesauce: Place one teaspoonful of room-temperature applesauce into a clean container.

Open the capsule.

Sprinkle the entire contents (beads) on applesauce.

Consume the entire contents immediately.

Do not chew the beads.

Do not store the bead-applesauce mixture for later use.

Oral Administration in Water: Pour approximately 30 mL of room-temperature bottled water into a clean cup.

Open the capsule.

Sprinkle the entire contents (beads) into the water.

Gently swirl beads and water for at least 20 seconds.

Swallow the entire mixture of beads and water immediately.

Add another 30 mL of water to any beads remaining in cup, swirl for 20 seconds, and swallow immediately.

Do not store the bead-water mixture for later use.

Note: The drug is coated on the surface of the beads and will dissolve off the beads into the water.

The beads will remain visible and will not dissolve.

Therefore, it is not necessary to consume all the beads to deliver the complete dose.

Administration with Water via a Nasogastric or Gastrostomy Tube: Open the capsule and empty the beads into a clean container with 30 mL of room-temperature bottled water.

Mix by gently swirling beads for at least 20 seconds.

Draw-up the beads and water mixture into an appropriately sized catheter-tipped syringe and apply rapid and steady pressure (10 mL/10 seconds) to dispense the syringe contents into the tube.

Add another 30 mL of water to any beads remaining in the container and repeat the process.

After administering the bead-water mixture, flush nasogastric/ gastrostomy tube with a minimum of 10 mL of water.

Note: It is not necessary to flush all the beads through to deliver the complete dose.